---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-053843"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:11:15.110936+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atea reports Q4 2022 net loss of $34.4M; provides clinical updates on COVID-19, HCV, and dengue programs

## Summary
- Net loss of $34.4M ($0.41 loss per share) in Q4 2022 vs net income of $117.1M in Q4 2021; full year 2022 net loss $115.9M.
- Revenue $0 in Q4 and full year 2022 vs $192.2M and $351.4M in 2021 due to end of Roche collaboration.
- Cash and marketable securities $646.7M at Dec 31, 2022, down from $764.4M at Dec 31, 2021.
- Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 continues enrollment; interim analysis expected 2H23.
- Dengue program deprioritized; Phase 2 HCV combination trial to start enrollment in 2Q23 with initial results by 4Q23.

## SEC filing metadata
- accession: 0001193125-23-053843
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312523053843/0001193125-23-053843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312523053843/d462845d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-053843
- JSON: https://secwatch.observer/filing/0001193125-23-053843.json
- Plain text: https://secwatch.observer/filing/0001193125-23-053843.txt

## Key facts
- Earnings Releases
  Atea Pharmaceuticals, Inc. reported financial results for Q4 and Full Year 2022.
  - Period: Q4 and Full Year 2022
  - Result: reported results
  source text: Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312523053843/0001193125-23-053843-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.